Summary: Patients with Renal Impairment

Recommendations for Patients With CKD Stagea 1, 2, or 3

RECOMMENDED RATING
No dose adjustment is required when using:
  • Daclatasvir (60 mg)b
  • Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)
  • Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c
  • Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
  • Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
  • Simeprevir (150 mg)
  • Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/
    voxilaprevir (100 mg)
  • Sofosbuvir (400 mg) 
I, A
a Chronic kidney disease (CKD) stages: 1 = normal (eGFR >90 mL/min); 2 = mild CKD (eGFR 60-89 mL/min); 3 = moderate CKD (eGFR 30-59 mL/min); 4 = severe CKD (eGFR 15-29 mL/min); 5 = end-stage CKD (eGFR <15 mL/min)
b Refer to the prescribing information and the section on HIV/HCV coinfection for patients on antiretroviral therapy.
c This is a 3-tablet coformulation. Please refer to the prescribing information.

 

Recommended regimens listed by evidence level and alphabetically for:

Patients With CKD Stagea 4 or 5 (eGFR <30 mL/min or End-Stage Renal Disease)

RECOMMENDED GENOTYPE DURATION RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) 1a, 1b, 4 12 weeks I, B
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b 1, 2, 3, 4, 5, 6 8 to 16 weeksc I, Bc
a Chronic kidney disease (CKD) stages: 1 = normal (eGFR >90 mL/min); 2 = mild CKD (eGFR 60-89 mL/min); 3 = moderate CKD (eGFR 30-59 ml/min); 4 = severe CKD (eGFR 15-29 mL/min); 5 = end-stage CKD (eGFR <15 mL/min)
b This is a 3-tablet coformulation. Please refer to the prescribing information.
c Patients in this group should be treated as would patients without CKD. Duration of glecaprevir/pibrentasvir should be based on presence of cirrhosis and prior treatment experience (please refer to appropriate section). As such, strength of rating may be lower for certain subgroups.

 

Last update: 
September 21, 2017
Top